WO2004045579A3 - Pharmaceutical compositions and dosage forms of thalidomide - Google Patents

Pharmaceutical compositions and dosage forms of thalidomide Download PDF

Info

Publication number
WO2004045579A3
WO2004045579A3 PCT/US2003/036620 US0336620W WO2004045579A3 WO 2004045579 A3 WO2004045579 A3 WO 2004045579A3 US 0336620 W US0336620 W US 0336620W WO 2004045579 A3 WO2004045579 A3 WO 2004045579A3
Authority
WO
WIPO (PCT)
Prior art keywords
dosage forms
thalidomide
pharmaceutical compositions
disclosed
clathrates
Prior art date
Application number
PCT/US2003/036620
Other languages
French (fr)
Other versions
WO2004045579A2 (en
Inventor
Angio Paul D
Original Assignee
Celgene Corp
Angio Paul D
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32326306&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2004045579(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to CA002505964A priority Critical patent/CA2505964C/en
Priority to NZ540545A priority patent/NZ540545A/en
Priority to DK03783567.5T priority patent/DK1562556T3/en
Priority to BR0316240-0A priority patent/BR0316240A/en
Priority to CN200380108803.9A priority patent/CN1738607B/en
Priority to EP03783567A priority patent/EP1562556B1/en
Priority to MXPA05005162A priority patent/MXPA05005162A/en
Priority to AU2003290982A priority patent/AU2003290982C1/en
Priority to SI200332255T priority patent/SI1562556T1/en
Priority to JP2004553785A priority patent/JP5269280B2/en
Application filed by Celgene Corp, Angio Paul D filed Critical Celgene Corp
Priority to ES03783567T priority patent/ES2403142T3/en
Publication of WO2004045579A2 publication Critical patent/WO2004045579A2/en
Publication of WO2004045579A3 publication Critical patent/WO2004045579A3/en
Priority to IL168585A priority patent/IL168585A/en
Priority to HK06109062.8A priority patent/HK1088543A1/en
Priority to AU2010201931A priority patent/AU2010201931A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers

Abstract

Pharmaceutical compositions and single unit dosage forms of thalidomide and pharmaceutically acceptable prodrugs, salts, solvates, hydrates, or clathrates are disclosed. Also disclosed are methods of treating and preventing diseases and conditions such as, but not limited to, leprosy, chronic graft-vs-host disease, rheumatoid arthritis, sarcoidosis, an inflammatory condition, inflammatory bowel disease, and cancer using the novel dosage forms disclosed herein.
PCT/US2003/036620 2002-11-14 2003-11-13 Pharmaceutical compositions and dosage forms of thalidomide WO2004045579A2 (en)

Priority Applications (14)

Application Number Priority Date Filing Date Title
ES03783567T ES2403142T3 (en) 2002-11-14 2003-11-13 Pharmaceutical compositions and dosage forms of thalidomide
JP2004553785A JP5269280B2 (en) 2002-11-14 2003-11-13 Pharmaceutical composition and dosage form of thalidomide
SI200332255T SI1562556T1 (en) 2002-11-14 2003-11-13 Pharmaceutical compositions and dosage forms of thalidomide
BR0316240-0A BR0316240A (en) 2002-11-14 2003-11-13 Unit dosage form and method for treating or preventing disease
NZ540545A NZ540545A (en) 2002-11-14 2003-11-13 Pharmaceutical compositions and dosage forms of thalidomide
EP03783567A EP1562556B1 (en) 2002-11-14 2003-11-13 Pharmaceutical compositions and dosage forms of thalidomide
MXPA05005162A MXPA05005162A (en) 2002-11-14 2003-11-13 Pharmaceutical compositions and dosage forms of thalidomide.
CA002505964A CA2505964C (en) 2002-11-14 2003-11-13 Pharmaceutical compositions and dosage forms of thalidomide
DK03783567.5T DK1562556T3 (en) 2002-11-14 2003-11-13 Pharmaceutical compositions and dosage forms of thalidomide
CN200380108803.9A CN1738607B (en) 2002-11-14 2003-11-13 Pharmaceutical compositions and dosage forms of thalidomide
AU2003290982A AU2003290982C1 (en) 2002-11-14 2003-11-13 Pharmaceutical compositions and dosage forms of thalidomide
IL168585A IL168585A (en) 2002-11-14 2005-05-15 Pharmaceutical compositions and dosage forms of thalidomide
HK06109062.8A HK1088543A1 (en) 2002-11-14 2006-08-15 Pharmaceutical compositions and dosage forms of thalidomide
AU2010201931A AU2010201931A1 (en) 2002-11-14 2010-05-13 Pharmaceutical compositions and dosage forms of thalidomide

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42601602P 2002-11-14 2002-11-14
US60/426,016 2002-11-14

Publications (2)

Publication Number Publication Date
WO2004045579A2 WO2004045579A2 (en) 2004-06-03
WO2004045579A3 true WO2004045579A3 (en) 2004-09-10

Family

ID=32326306

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/036620 WO2004045579A2 (en) 2002-11-14 2003-11-13 Pharmaceutical compositions and dosage forms of thalidomide

Country Status (19)

Country Link
US (1) US7230012B2 (en)
EP (2) EP1562556B1 (en)
JP (2) JP5269280B2 (en)
KR (1) KR100671366B1 (en)
CN (2) CN101816626A (en)
AU (2) AU2003290982C1 (en)
BR (1) BR0316240A (en)
CA (1) CA2505964C (en)
DK (1) DK1562556T3 (en)
ES (1) ES2403142T3 (en)
HK (1) HK1088543A1 (en)
IL (1) IL168585A (en)
MX (1) MXPA05005162A (en)
NZ (1) NZ540545A (en)
PT (1) PT1562556E (en)
SI (1) SI1562556T1 (en)
TW (2) TWI377062B (en)
WO (1) WO2004045579A2 (en)
ZA (1) ZA200503927B (en)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7230012B2 (en) * 2002-11-14 2007-06-12 Celgene Corporation Pharmaceutical compositions and dosage forms of thalidomide
US7838029B1 (en) 2003-07-31 2010-11-23 Watson Laboratories, Inc. Mirtazapine solid dosage forms
US7390503B1 (en) 2003-08-22 2008-06-24 Barr Laboratories, Inc. Ondansetron orally disintegrating tablets
US20100173864A1 (en) 2004-03-29 2010-07-08 Cheng Jin Q Compositions including triciribine and one or more platinum compounds and methods of use thereof
US20100009929A1 (en) 2004-03-29 2010-01-14 Cheng Jin Q Compositions including triciribine and bortezomib and derivatives thereof and methods of use thereof
MXPA06011219A (en) 2004-03-29 2007-05-08 Univ South Florida Effective treatment of tumors and cancer with triciribine and related compounds.
US20100009928A1 (en) * 2004-03-29 2010-01-14 Cheng Jin Q Compositions including triciribine and taxanes and methods of use thereof
US20110008327A1 (en) * 2004-03-29 2011-01-13 Cheng Jin Q Compositions including triciribine and epidermal growth factor receptor inhibitor compounds or salts thereof and methods of use thereof
US20100028339A1 (en) 2004-03-29 2010-02-04 Cheng Jin Q Compositions including triciribine and trastuzumab and methods of use thereof
US7534381B2 (en) * 2005-09-14 2009-05-19 Isp Investments Inc. Process and apparatus for forming agglomerates of a powder composition of an active and binder
CN1870631B (en) * 2005-11-11 2010-04-14 华为技术有限公司 Gate control method of media gateway
KR101462693B1 (en) * 2006-08-16 2014-11-17 노파르티스 아게 Method for making solid dispersions of highly crystalline therapeutic compounds
US20110110984A1 (en) * 2006-11-10 2011-05-12 Alphaptose Gmbh Oral Dosage Form Comprising Tri-Substituted Glycerol Compounds
US20090137631A1 (en) * 2007-11-22 2009-05-28 National Yang-Ming University Methods and pharmaceutical compositions for regulation of g- and/or gc-rich nucleic acid expression
DK3351240T3 (en) 2009-05-19 2019-06-17 Celgene Corp FORMULATIONS OF 4-AMINO-2- (2,6-DIOXOPIPERIDIN-3-YL) ISOINDOLIN-1,3-DION
KR101369936B1 (en) * 2011-12-28 2014-03-06 연세대학교 산학협력단 Pharmaceutical composition for treating lupus nephritis comprising thalidomide
JP5087182B1 (en) 2012-06-13 2012-11-28 クリニプロ株式会社 Method for producing inhalable powder
WO2015116802A1 (en) 2014-01-29 2015-08-06 Otsuka Pharmaceutical Co., Ltd. Device-based risk management of a therapeutic
CN106137986B (en) * 2015-03-09 2019-04-16 常州制药厂有限公司 A kind of Thalidomide piece and preparation method thereof
CN106138052B (en) * 2015-04-16 2020-02-21 欣凯医药化工中间体（上海）有限公司 Thalidomide preparation and preparation method thereof
US20200254093A1 (en) 2017-09-14 2020-08-13 Glaxosmithkline Intellectual Property Development Limited Combination treatment for cancer
WO2019099868A2 (en) 2017-11-16 2019-05-23 C4 Therapeutics, Inc. Degraders and degrons for targeted protein degradation
US10537585B2 (en) 2017-12-18 2020-01-21 Dexcel Pharma Technologies Ltd. Compositions comprising dexamethasone
JP2021519337A (en) 2018-03-26 2021-08-10 シー４ セラピューティクス， インコーポレイテッド Cereblon binder for the degradation of Ikaras
CN112312904A (en) 2018-04-16 2021-02-02 C4医药公司 Spiro compounds
WO2020051235A1 (en) 2018-09-04 2020-03-12 C4 Therapeutics, Inc. Compounds for the degradation of brd9 or mth1
KR20200054046A (en) 2018-11-09 2020-05-19 한국화학연구원 Novel piperidine-2,6-dione derivatives and use thereof
WO2020132561A1 (en) 2018-12-20 2020-06-25 C4 Therapeutics, Inc. Targeted protein degradation
EP3935050A4 (en) 2019-03-06 2023-01-04 C4 Therapeutics, Inc. Heterocyclic compounds for medical treatment
KR20230068335A (en) 2021-11-09 2023-05-17 한국화학연구원 Glutarimide moiety based isoindolinone derivatives and use thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001074362A1 (en) * 2000-03-31 2001-10-11 Celgene Corporation Inhibition of cyclooxygenase-2 activity
WO2003080048A1 (en) * 2002-03-20 2003-10-02 Celgene Corporation (-)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992014455A1 (en) 1991-02-14 1992-09-03 The Rockefeller University METHOD FOR CONTROLLING ABNORMAL CONCENTRATION TNF α IN HUMAN TISSUES
US5629327A (en) 1993-03-01 1997-05-13 Childrens Hospital Medical Center Corp. Methods and compositions for inhibition of angiogenesis
US6228879B1 (en) 1997-10-16 2001-05-08 The Children's Medical Center Methods and compositions for inhibition of angiogenesis
US6114355A (en) 1993-03-01 2000-09-05 D'amato; Robert Methods and compositions for inhibition of angiogenesis
US5405855A (en) 1993-12-23 1995-04-11 Andrulis Pharmaceuticals Corp. Treatment of insulin resistant diabetes with thalidomine
US5434170A (en) 1993-12-23 1995-07-18 Andrulis Pharmaceuticals Corp. Method for treating neurocognitive disorders
US6001828A (en) 1995-06-05 1999-12-14 Andrulis, Jr.; Peter Use of tumor factor inhibitors together with antiviral agents and therapeutic compositions thereof against HIV infection
US5643915A (en) * 1995-06-06 1997-07-01 Andrulis Pharmaceuticals Corp. Treatment of ischemia/reperfusion injury with thalidomide alone or in combination with other therapies
US5731325A (en) 1995-06-06 1998-03-24 Andrulis Pharmaceuticals Corp. Treatment of melanomas with thalidomide alone or in combination with other anti-melanoma agents
US5654312A (en) 1995-06-07 1997-08-05 Andrulis Pharmaceuticals Treatment of inflammatory and/or autoimmune dermatoses with thalidomide alone or in combination with other agents
DK1586322T3 (en) 1996-11-05 2008-12-01 Childrens Medical Center Compositions containing thalidomide and dextamethasone for the treatment of cancer
CA2319872C (en) * 2000-02-02 2012-06-19 Chun-Ying Huang Pharmaceutical composition for the treatment of hepatocellular carcinoma
NZ522766A (en) * 2000-05-15 2005-09-30 Celgene Corp Compositions and methods for the treatment of colorectal cancer with irinotecan and thalidomide to reduce side effects
US7230012B2 (en) * 2002-11-14 2007-06-12 Celgene Corporation Pharmaceutical compositions and dosage forms of thalidomide

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001074362A1 (en) * 2000-03-31 2001-10-11 Celgene Corporation Inhibition of cyclooxygenase-2 activity
WO2003080048A1 (en) * 2002-03-20 2003-10-02 Celgene Corporation (-)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
S. TEO, M. EVANS, J. EHRHART, M. BROCKMAN: "Lack of peripheral neurophathy in Beagle dogs after 53 weeks oral administration of thalidomide capsules", HUMAN AND EXPERIMENTAL TOXICOLOGY, vol. 19, 2000, pages 615 - 622, XP008031450 *
S.K TEO, M.R. SCHEFFLER, K.A. KOOK: "Effect of a high-fat Meal on thalidomide pharmacokinetics and the relative bioavailability of oral formulations in healthy men and women", BIOPHARMACEUTICS AND DRUG DISPOSITION, vol. 21, 2000, pages 33 - 40, XP008031447 *
T.E. CLARK, N.E. EDOM, J. LARSON, L. LINDSEY: "Thalomid (Thalidomide) Capsules", DRUG SAFETY, vol. 24, no. 2, 2001, XP008031449 *

Also Published As

Publication number Publication date
US20040138263A1 (en) 2004-07-15
US7230012B2 (en) 2007-06-12
CA2505964C (en) 2009-07-28
EP1562556A2 (en) 2005-08-17
JP5269280B2 (en) 2013-08-21
PT1562556E (en) 2013-04-23
IL168585A (en) 2015-01-29
AU2003290982C1 (en) 2010-10-07
AU2003290982B2 (en) 2009-07-02
ZA200503927B (en) 2006-08-30
BR0316240A (en) 2005-10-11
AU2003290982A1 (en) 2004-06-15
KR20050086624A (en) 2005-08-30
CN1738607A (en) 2006-02-22
CN1738607B (en) 2014-05-14
CN101816626A (en) 2010-09-01
JP2006508983A (en) 2006-03-16
SI1562556T1 (en) 2013-05-31
TWI377062B (en) 2012-11-21
CA2505964A1 (en) 2004-06-03
NZ540545A (en) 2007-10-26
TW200505449A (en) 2005-02-16
TWI359659B (en) 2012-03-11
DK1562556T3 (en) 2013-03-25
AU2010201931A1 (en) 2010-07-01
WO2004045579A2 (en) 2004-06-03
EP1562556B1 (en) 2013-01-23
TW200731973A (en) 2007-09-01
EP2277512A2 (en) 2011-01-26
EP2277512A3 (en) 2012-07-04
ES2403142T3 (en) 2013-05-14
MXPA05005162A (en) 2005-07-22
JP2009215310A (en) 2009-09-24
HK1088543A1 (en) 2006-11-10
KR100671366B1 (en) 2007-01-19
JP4927905B2 (en) 2012-05-09

Similar Documents

Publication Publication Date Title
WO2004045579A3 (en) Pharmaceutical compositions and dosage forms of thalidomide
MXPA04003439A (en) 3,4-di-substituted maleimide compounds as cxc-chemokine receptor antagonists.
MXPA05010958A (en) Indazole derivatives as jnk inhibitors.
AU3664401A (en) Platelet adp receptor inhibitors
EP2260835A3 (en) Composition for proteasome inhibition
MY162174A (en) Azetidines mek inhibitors for the treatment of proliferative diseases
MXPA04006555A (en) 3,4-di-substituted pyridazinediones as cxc chemokine receptor antagonists.
MY148125A (en) Compounds
HK1062677A1 (en) 17Beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
BRPI0513843A (en) compound or a pharmaceutically acceptable salt or solvate or prodrug thereof, pharmaceutical composition, dosage form, use of a compound, and hydrochloride salt
NO20050851L (en) Caspase Inhibitors and Uses thereof
CY1108625T1 (en) PHARMACEUTICAL COMPOSITIONS FOR ADMINISTRATION FROM US ORAL OR PRODUCERS
WO2001035950A3 (en) Benzamide therapeutics and methods for treating inflammatory bowel disease
NO20044562L (en) Methods for treating bowel disease
WO2003065987A3 (en) Granzyme b inhibitors
WO2003094921A3 (en) Utilization of inhibitors of egfr-mediated signal transduction for the treatment of benign prostatic hyperplasia (bph)/prostatic hypertrophy
WO2003106450A8 (en) Phenylaminopyrimidines and their use as rho-kinase inhibitors
RS20060662A (en) 4-phenyl-pyrimidine-2-carbonitrile derivatives
TW200507829A (en) New combination
NO20071399L (en) VLA-4 antagonists
MX2008001608A (en) Acetylenic piperazines as metabotropic glutamate receptor antagonists.
WO2008005352A3 (en) Solid dose formulations of a thrombin receptor antagonist
NO20054346L (en) Compositions and methods for the prevention and treatment of endotoxin-related diseases and conditions
DE69917005D1 (en) SUBSTITUTED PYRROLOBENZIMIDAZOLE DERIVATIVES FOR ANTI-INFLAMMATION
HK1072012A1 (en) 5-ht4 receptor antagonists for the treatment of heart failure

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2505964

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: PA/a/2005/005162

Country of ref document: MX

Ref document number: 2004553785

Country of ref document: JP

Ref document number: 1020057008631

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 168585

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2005/03927

Country of ref document: ZA

Ref document number: 200503927

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 540545

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2003783567

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2003290982

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 20038A88039

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2003783567

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020057008631

Country of ref document: KR

ENP Entry into the national phase

Ref document number: PI0316240

Country of ref document: BR